Find a Trial

Advancing investigational treatment options for people living with cancer.

Cancer

Solid Tumors

Rubius Therapeutics® is enrolling adults with relapsed/refractory or locally advanced solid tumor cancers into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-240. There are two Phase 1 arms enrolling adult patients with advanced solid tumor cancers – one to evaluate RTX-240 as monotherapy and the other to evaluate RTX-240 in combination with KEYTRUDA® (pembrolizumab)1.

LEARN MORE ABOUT THE RTX-240 CLINICAL TRIAL

Acute Myeloid Leukemia

Rubius Therapeutics is enrolling adults with relapsed acute myeloid leukemia (AML) or refractory AML into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-240.

LEARN MORE ABOUT THE RTX-240 CLINICAL TRIAL

HPV 16-Associated Cancers

Rubius Therapeutics is enrolling adults with human papilloma virus (HPV) 16-associated cancers, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer) into a Phase 1 clinical trial to evaluate an investigational potential treatment option, called RTX-321. You may be eligible to participate even if you do not know if your cancer is associated with HPV 16.

LEARN MORE ABOUT THE RTX-321 CLINICAL TRIAL

References:

  1. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


Thank you

We will contact you about your submission